During the 2014-2015 Ebola virus disease outbreak in West Africa, MSF built a number of Ebola Treatment Centres (ETCs). MSF set up centres in the three countries at different moments and with different MSF Operational Sections, which resulted in a heterogenic collection of solutions. This review was conducted jointly for all MSF operational centers (OCs). It was commissioned by OCA and was conducted as part of the OCB Ebola review. 

OCB initiated the Kibera project at a time when there was a lack of access to affordable HIV/TB health care and succeeded in providing HIV drugs in Kenya, against all odds. The initial decision to intervene in Kibera was based on need and while the needs remain massive, OCB is no longer alone in providing HIV and TB treatment, hence the opportunity to handover the responsibilities of the health facilities to the Nairobi County to ensure that the population is not abandoned and that the quality care and treatment is continued.

In October 2013 MSF developed a proposal for a new WHS strategy for meeting the medical humanitarian needs in large scale emergencies. In May 2015, the MSF Stockholm Evaluation Unit commissioned an evaluation of the 2013 MSF Operational Centre Amsterdam (OCA) strategy for a more offensive WHS approach. The evaluation focused on OCA interventions in South Sudan in Jaman, 2012, Bentui in 2014, CAR/Bossangoa and Bangui in 2014 and Ethiopia/Gambella in 2014. The period of evaluation was the first 3 months of the interventions.

In 2010 the operational prospects for OCB (strategic operational plan) outlined the broad objectives for the coming three years and placed renewed attention on key medical areas including surgery and emergency and acute medicine, bringing about increased investment in two hospital programs where OCB focussed on providing emergency surgical care in third level facilities in Tabarre and Kunduz.

Between late 2010 and the end of 2014 and under extremely difficult conditions, Médecins sans Frontières (MSF) carried out a project to combat Human African trypanosomiasis (HAT), also known as sleeping sickness, in the Dingila, Ango and Zobia regions of Orientale Province in the Democratic Republic of Congo (DRC). HAT in DRC is caused by Trypanosoma brucei gambiense and is transmitted by the tsetse fly (Glossina genus) of the Palpalis group. Without effective treatment, virtually all first-stage HAT patients and one hundred per cent of second-stage patients will die.

This evaluation of MSF OCP concerns the review of MSF-OCP's emergency intervention for South-Sudanese refugees in Ethiopia, early 2014 (part of an intentional global review of MSF response to crises with major population Displacement - decision IB/5 DG, 2014). Here in Gambella, the response to well-known 11 priorities/refugee needs is checked out systematically - while the initial reactivity is fair, there are some limitations concerning know how in key operational domains (cf details in report).

Entre fin 2010 et fin 2014, Médecins sans Frontières (MSF) a, dans des conditions extrêmement difficiles, mené un projet de lutte contre la trypanosomiase humaine africaine (THA) ou maladie du sommeil dans la région de Dingila, Ango et Zobia, dans la Province Orientale de la République Démocratique du Congo (RDC). La THA en RDC est causée par Trypanosoma brucei gambiense et y est transmise par des glossines (mouches tsé-tsé) du groupe palpalis. Sans traitement efficace, quasi tous les malades au premier stade et cent pourcent de malades au deuxième stade de la THA meurent.

Between late 2010 and the end of 2014 and under extremely difficult conditions, Médecins sans Frontières (MSF) carried out a project to combat Human African trypanosomiasis (HAT), also known as sleeping sickness, in the Dingila, Ango and Zobia regions of Orientale Province in the Democratic Republic of Congo (DRC). HAT in DRC is caused by Trypanosoma brucei gambiense and is transmitted by the tsetse fly (Glossina genus) of the Palpalis group. Without effective treatment, virtually all first-stage HAT patients and one hundred per cent of second-stage patients will die.

Entre fin 2010 et fin 2014, Médecins sans Frontières (MSF) a, dans des conditions extrêmement difficiles, mené un projet de lutte contre la trypanosomiase humaine africaine (THA) ou maladie du sommeil dans la région de Dingila, Ango et Zobia, dans la Province Orientale de la République Démocratique du Congo (RDC). La THA en RDC est causée par Trypanosoma brucei gambiense et y est transmise par des glossines (mouches tsé-tsé) du groupe palpalis. Sans traitement efficace, quasi tous les malades au premier stade et cent pourcent de malades au deuxième stade de la THA meurent.

Chemical prevention of seasonal malaria (CPS) has been implemented in Niger since 2013, pursuant to the recommendations of the World Health Organization (WHO) and the national anti-malaria policy. It consists of a mass campaign involving the administration of curative doses of sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) to children between the ages of 3 and 59 months for three days, at 28-day intervals, between July and November.

Pages